Other

To the Editor: Chan et al. (Feb. 13 issue)¹ report the results of the phase 3 CABINET (Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Prior Therapy) trial. Cabozantinib, as compared with placebo, significantly improved progression-free survival among patients with previously treated, progressive...

To the Editor: In the HELIOS-B trial, Fontana et al. (Jan. 2 issue)¹ showed the efficacy of vutrisiran in reducing the risk of death and cardiovascular events in transthyretin amyloidosis with cardiomyopathy (ATTR-CM). However, they insufficiently explored kidney function, a possible determinant of prognosis in ATTR-CM.²

To the Editor: Only 82 children of the 160 million who are obese worldwide¹ were studied in the SCALE Kids trial (Feb. 6 issue),² which suggests that the pharmaceutical sponsor had little interest in pediatric patients. In contrast to robustly funded studies involving adults (ClinicalTrials.gov...

Pegivirus hominis, a common virus that has not been linked to specific diseases, was detected in CSF, serum, and brain tissue from four patients with encephalomyelitis, with evidence of independent replication in the CNS.

To the Editor: The letter by Hoshino and coworkers (Jan. 30 issue)¹ hypothesizes an immune-mediated pathogenesis of tumor-induced osteomalacia in patients in whom the neoplasia was not localized. This suggestion may open the way to new therapeutic options in addition to conventional and burosumab treatments. However, we...

To the Editor: The review article by Fasano (Jan. 23 issue)¹ concerning human nutrition and hunger regulation omits the crucial role of autophagy, a cellular recycling process vital for maintaining energy homeostasis. Autophagy functions as a critical cellular response to nutrient deprivation by enabling the mobilization of...

Relapsed Burkitt’s lymphoma is nearly always fatal. Three patients had a complete metabolic response with the combination of the bispecific antibody glofitamab and the antibody–drug conjugate polatuzumab vedotin.

To the Editor: The recent gene-therapy trial for the treatment of hemophilia A by Srivastava et al. (Jan. 30 issue)¹ is an important advancement in Indian research. The use of autologous CD34+ cells transduced with a lentivirus-expressing porcine factor VIII under a CD68 promoter (CD68-ET3-LV)² ...

To the Editor: In their trials comparing initial intraosseous and intravenous attempts at vascular access for out-of-hospital cardiac arrest, Vallentin et al.¹ found no significant difference in the return of spontaneous circulation, and Couper et al.² found no significant difference in survival at 30 days...

To the Editor: In the POPular PAUSE TAVI (Periprocedural Continuation versus Interruption of Oral Anticoagulant Drugs during Transcatheter Aortic Valve Implantation) trial, van Ginkel et al. (Jan. 30 issue)¹ found that among patients undergoing transcatheter aortic-valve implantation (TAVI) who were being treated with oral anticoagulation, the continuation...

A CMS health-equity incentive for dialysis facilities reduced financial penalties for facilities that serve patients with more social risk factors but did not narrow disparities in clinical outcomes.

To the Editor: Packer et al. (Jan. 30 issue)¹ report the highly anticipated results of the SUMMIT trial, which compared tirzepatide with placebo in patients with heart failure with preserved ejection fraction and assessed clinical end points over a 1-year period. The trial showed a lower risk...

To the Editor: Gbadegesin et al. (Jan. 16 issue)¹ conducted an insightful study on apolipoprotein L1 gene (APOL1) bi- and monoallelic variants and chronic kidney disease (CKD) in West Africans. This work advances our understanding of APOL1 -associated kidney disease in this population considerably....

To the Editor: Much of the science in the review article on hemophagocytic lymphohistiocytosis (HLH) by Henter (Feb. 6 issue)¹ is based on primary HLH in children. Diagnosing secondary HLH in adults remains challenging. Adult HLH is characterized more by hyperinflammation than by defective lymphocyte cytotoxicity, and...

A patient with poorly controlled HIV infection was found to have two different strains of Treponema pallidum. Careful evaluation showed evidence for recombination between these two organisms.

To the Editor: The AZALEA–TIMI 71 trial reported by Ruff et al. (Jan. 23 issue)¹ compared abelacimab with rivaroxaban in patients with atrial fibrillation. A key concern is whether rivaroxaban remains the most appropriate control. Before patients enrolled in this trial, the best available evidence suggested that...

To the Editor: As shown in a trial reported by Hoeppner et al. (Jan. 23 issue),¹ the survival benefits of FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) in patients with esophageal adenocarcinoma are clear, but the associated long-term toxic effects and effects on health-related quality of life need...

To the Editor: In the article by Bolland et al. (Jan. 16 issue)¹ assessing zoledronate in early postmenopausal women (50 to 60 years of age), two points warrant clarification. First, vitamin D status can possibly influence bone health and fracture risk.² Did the authors measure...

To the Editor: The results of the PICNIC trial reported by Ullman et al. (Jan. 9 issue)¹ provide valuable insights into materials used in peripherally inserted central catheters (PICCs). However, two issues warrant further clarification. First, the authors report a higher incidence of catheter occlusion with the...

Patients with hairy-cell leukemia lacking the BRAF V600E mutation often have a BRAF deletion or activating mutation in MAP2K1, with a poor response to standard therapy. Dabrafenib plus trametinib was active in one patient.